Although the reported patients do not fit the stereotypic pattern of extrinsic atopic dermatitis characterized by a combination of typical cutaneous features, childhood onset, and mucosal allergies (rhinitis or asthma), they do fit the well-described intrinsic atopic dermatitis phenotype characterized by typical skin lesions, adult onset, and lack of mucosal allergies. 4 In addition, they meet the Hanifin and Rajka criteria for diagnosis of atopic dermatitis.
Low conversion rate of QuantiFERON-TB Gold screening tests in patients treated with tumor necrosis factor inhibitors: A retrospective cohort study identifying an important practice gap
To the Editor: Conflicting guidelines exist among different specialties regarding the need for annual tuberculosis (TB) screening in patients undergoing treatment with tumor necrosis factor (TNF) inhibitors, leading to an important practice gap. The National Psoriasis Foundation recommends annual TB screening in all of these patients, 1 while the American College of Rheumatology recommends annual screening in patients with risk factors for TB. 2 There are few longitudinal studies examining the need for rescreening in this patient population. We sought to determine the TB conversion rate in patients undergoing anti-TNF treatment in Iowa, an area with low TB prevalence; in 2016, the TB case rate in Iowa was 1.54 cases/100,000 persons. 3 We conducted a single-center retrospective cohort study to determine the rate of conversion of QuantiFERON-TB Gold In-Tube (QFT-GIT) tests in patients on anti-TNF therapy. We evaluated all patients seen at the University of Iowa Hospitals and Clinics during January 2009-November 2017 with at least 2 interpretable QFT-GIT tests and a prescription history of a TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, or golimumab). Patients were excluded if they had a baseline positive QFT-GIT test, if all tests were performed outside of the anti-TNF treatment period, if total duration of anti-TNF therapy was \30 days, or if the tests were separated by \30 days. We also performed a search for all patients with a negative QFT-GIT test and prescription history of a TNF inhibitor and isoniazid, to evaluate for any patients who were treated for TB. The study was approved by the institutional review board.
A total of 265 patients with negative baseline TB screening were enrolled. Patient characteristics are summarized in Table I . The prescribing specialty included dermatology (114; 43%), gastroenterology (91; 34.3%), and rheumatology (60; 22.6%). Indications for treatment included psoriasis (100; 37.7%), inflammatory bowel disease (91; 34.3%), and inflammatory arthritis (55; 20.8%). In total 122 (46%) patients had a history of treatment with [1 TNF inhibitor. The median duration of anti-TNF therapy was 3.5 (interquartile range [IQR] 1.9-5.8) years, and the median duration between TB tests was 1.3 (IQR 1.0-2.0) years. Out of 265 patients, there was only 1 patient (0.4%) who converted (Table II) . The patient was asymptomatic without any risk factors for TB and had a negative chest X-ray. While there was concern for a false positive test, he was treated for latent TB infection (LTBI). There were no cases of active TB that developed during or following anti-TNF therapy among patients with a negative baseline TB test.
To our knowledge, this is the first multispecialty study conducted in a low-prevalence area in the United States to evaluate the rate of TB test conversion in patients on anti-TNF therapy. Our main limitation is that we had a relatively small number of patients in our single-center study. We also only evaluated patients who received QFT-GIT tests as the TB screening method.
Our study shows an extremely low proportion of patients (0.4%) who converted during TNFinhibitor therapy, or 1 in 1106.5 person-years. The sensitivity and specificity of the QFT-GIT for LTBI in non-BCGevaccinated patients have been reported as 52%-70% and 97%-99%, respectively. 4, 5 Its positive and negative predictive values vary by prevalence, but the positive predictive value of serial QFT testing in low-risk areas can be #60%.
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Serial testing using interferon-release assays is controversial due to frequent conversions and reversions. 7 When the tests are repeated without treatment, the converters often revert to negative results. 8 On the basis of these findings, serial TB testing in a low-risk population might result in a higher likelihood of false-positive test results, increased costs associated with follow-up and unnecessary treatment, and increased risk for adverse events. Consolidated TB screening guidelines that recommend baseline screening in all patients and limit annual screening in low-prevalence areas only to those with TB risk factors (health care workers, close contacts of persons with known or suspected active TB, foreign-born persons from areas of high TB prevalence, injection drug users, residents, and employees of high-risk congregate settings, including correctional facilities, long-term care facilities, and homeless shelters) would help reduce costs and unnecessary testing. 
